Polyoxometalate nanoclusters: A potential preventative and therapeutic drug for inflammatory bowel disease

被引:31
|
作者
Wang, Jingguo [1 ]
Tao, Zhenchao [2 ]
Tian, Tian [3 ]
Qiu, Jun [2 ]
Qian, Haisheng [4 ]
Zha, Zhengbao [1 ]
Miao, Zhaohua [1 ]
Ma, Yan [1 ]
Wang, Hua [3 ,5 ]
机构
[1] Hefei Univ Technol, Sch Food & Biol Engn, Hefei 230009, Anhui, Peoples R China
[2] Anhui Prov Canc Hosp, Dept Radiat Oncol, Hefei 230031, Peoples R China
[3] Anhui Med Univ, Affiliated Hosp 1, Dept Oncol, Hefei 230022, Peoples R China
[4] Anhui Med Univ, Sch Biomed Engn, Res & Engn Ctr Biomed Mat, Hefei 230032, Peoples R China
[5] Inflammat & Immune Mediated Dis Lab Anhui Prov, Hefei 230032, Peoples R China
基金
中国国家自然科学基金;
关键词
Inflammatory bowel disease; Reactive oxygen species; Polyoxometalate nanoclusters; Anti-inflammation therapy; QUALITY-OF-LIFE; EXPERIMENTAL COLITIS; ULCERATIVE-COLITIS; RISK-FACTOR; PATHOGENESIS; CLUSTER; COPPER;
D O I
10.1016/j.cej.2021.129137
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Although the etiology and pathogenesis of refractory inflammatory bowel diseases (IBD) are still largely suspended, elimination of reactive oxygen species (ROS) in inflamed colon has been confirmed as an effective strategy to alleviate IBD. In this work, ROS scavengable tungsten (W)-based polyoxometalate nanoclusters (WPOM NCs) were explored as potential POMs-based medicine for safe and effective IBD preventative/therapeutic therapy. Due to the existence of W element with mixed valence state, W-POM NCs with good stability and biosafety could be non-invasively monitored by clinical computed tomography (CT) after oral administration and alleviate intestinal inflammation by scavenging multiple ROS as evidenced by reduced colonic damage, disease activity index (DAI) scores and levels of pro-inflammatory cytokines in an acute colitis mouse model. Therefore, our work pioneered the application of POMs with ROS scavenge capability for the treatment of IBD without significant adverse effects.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] IKKα AS A POTENTIAL THERAPEUTIC TARGET FOR THE PREVENTION OF INFLAMMATORY BOWEL DISEASE
    Tang, Joseph
    Papoutsopoulou, Stamatia
    Paul, Andrew
    MacKay, Professor Simon
    Duckworth, Carrie
    Pritchard, Mark
    GUT, 2021, 70 : A126 - A127
  • [42] Therapeutic potential of flavonoids in inflammatory bowel disease: A comprehensive review
    Ali Salaritabar
    Behrad Darvishi
    Farzaneh Hadjiakhoondi
    Azadeh Manayi
    Antoni Sureda
    Seyed Fazel Nabavi
    Leo R Fitzpatrick
    Seyed Mohammad Nabavi
    Anupam Bishayee
    World Journal of Gastroenterology, 2017, (28) : 5097 - 5114
  • [43] Therapeutic Potential to Modify the Mucus Barrier in Inflammatory Bowel Disease
    Sun, Jing
    Shen, Xiao
    Li, Yi
    Guo, Zhen
    Zhu, Weiming
    Zuo, Lugen
    Zhao, Jie
    Gu, Lili
    Gong, Jianfeng
    Li, Jieshou
    NUTRIENTS, 2016, 8 (01):
  • [44] TRP channels in inflammatory bowel disease: Potential therapeutic targets
    Du, Yaoyao
    Chen, Jie
    Shen, Lan
    Wang, Bing
    BIOCHEMICAL PHARMACOLOGY, 2022, 203
  • [45] The therapeutic potential of histamine receptor ligands in inflammatory bowel disease
    Neumann, Detlef
    Seifert, Roland
    BIOCHEMICAL PHARMACOLOGY, 2014, 91 (01) : 12 - 17
  • [46] Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug?
    Papamichael, Konstantinos
    Cheifetz, Adam S.
    CURRENT OPINION IN GASTROENTEROLOGY, 2019, 35 (04) : 302 - 310
  • [47] The potential therapeutic role of vitamin D in inflammatory bowel disease
    Boccuzzi, L.
    Infante, M.
    Ricordi, C.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (10) : 4678 - 4687
  • [48] LACTULOSE - A POTENTIAL-DRUG FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
    LIAO, W
    CUI, XS
    JIN, XY
    FLOREN, CH
    MEDICAL HYPOTHESES, 1994, 43 (04) : 234 - 238
  • [49] Preventative Care in the Patient with Inflammatory Bowel Disease: What Is New?
    Jason S. Reich
    Francis A. Farraye
    Sharmeel K. Wasan
    Digestive Diseases and Sciences, 2016, 61 : 2205 - 2216
  • [50] Therapeutic Drug Monitoring in Inflammatory Bowel Disease History and Future Directions
    Spencer, Elizabeth A.
    Dubinsky, Marla C.
    PEDIATRIC CLINICS OF NORTH AMERICA, 2017, 64 (06) : 1309 - +